ImExHS (IME) AGM 2026 presentation summary
Event summary combining transcript, slides, and related documents.
AGM 2026 presentation summary
20 May, 2026Leadership and governance
Board includes experienced non-executive directors and a CEO with medical and operational expertise.
Management team covers finance, operations, sales, and medical leadership roles.
Business overview and strategy
Operates two core businesses: medical imaging software and radiology services, primarily in Colombia.
Focus on democratising access to medical imaging expertise.
Strategic emphasis on automation, AI-driven workflows, and selective portfolio management.
Operational and financial performance
FY25 revenue reached $29.0m, up 10% year-over-year, with ARR at $34.8m, up 16%.
Underlying EBITDA for FY25 was $1.6m, at the top end of guidance.
Cash increased to $3.3m and debt reduced to $0.5m by year-end.
Q1 FY26 revenue grew 13% to $7.9m, with EBITDA at $0.8m.
Latest events from ImExHS
- Strong Q1 FY26 growth driven by AI-native platform and robust software/services performance.IME
Q1 2026 TU30 Apr 2026 - Revenue up 10%, EBITDA tripled to AUD 1.6m, ARR up 16%, and cash flow turned positive.IME
H2 20253 Mar 2026 - Revenue up 56.6% and ARR up 21%, but going concern risks remain due to cash outflows.IME
H1 202422 Jan 2026 - Revenue up 34% and ARR up 20%, driven by recurring income and margin improvements.IME
H2 202424 Dec 2025 - Q3 FY25 delivered 9% revenue and 24% ARR growth, margin gains, and reaffirmed FY25 guidance.IME
Q3 2025 TU13 Nov 2025 - ARR up 11% to $32.8m, revenue up 4%, with new product launches and FY25 growth guidance.IME
H1 202520 Oct 2025 - Robust financial growth and strategic software rollout drive positive 2025 outlook.IME
AGM 20256 Jun 2025